AGC Biologics announces strategic partnership with RoosterBio

KUALA LUMPUR, Aug 17 (Bernama) -- AGC Biologics, a leading global biopharmaceutical contract development and manufacturing organisation (CDMO), has announced a strategic partnership with RoosterBio Inc.

RoosterBio is a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media and bioprocess development services.

The partnership creates an end-to-end solution for the development and production of hMSCs and exosome therapeutics leveraging RoosterBio’s well-established cell and media products and process development services, coupled with AGC Biologics’ global cell and gene therapy manufacturing capabilities.

“AGC Biologics is happy to be partnering with RoosterBio. They have a reliable method for producing engineered cells and exosomes that can help developers create life-saving therapies,” AGC Biologics chief executive officer Patricio Massera said in a statement.

“When you combine their work and expertise with AGC Biologics' scientific knowledge and global manufacturing services, it creates a comprehensive offering that can help these developers save time and money, and get their treatments in the hands of patients in need.”

RoosterBio will utilise its extensive portfolio of cell and media products to develop robust, scalable processes for hMSC and exosome therapies.

Meanwhile, AGC Biologics will utilise its global network to provide full process development, cGMP manufacturing, quality control and regulatory services for pre-clinical and phase I/II clinical trials, with the ability to scale to phase III and commercial production.

More details at www.agcbio.com.

-- BERNAMA